The stability landscape of mRNA vaccines: challenges and mitigation strategies

Mar 25, 2026Vaccine

How mRNA Vaccines Stay Stable: Problems and Ways to Improve

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

mRNA vaccines face significant stability challenges that limit their effective use.

Molecular degradation, cold-chain requirements, and limited shelf life are key factors affecting mRNA vaccine stability.
Vulnerabilities at the molecular level include sites prone to breakdown and sensitivity to enzymes that degrade RNA.
The stability of lipid nanoparticles used for mRNA delivery is influenced by their structure and composition.
Environmental factors such as temperature, acidity, and the presence of degrading enzymes also affect vaccine stability.
Innovative strategies to enhance stability include molecular modifications of mRNA and advanced designs for lipid nanoparticles.
Techniques like freeze-drying may allow storage at room temperature, potentially increasing vaccine accessibility.

AI simplified

mRNA vaccines have emerged as a transformative platform in vaccinology, offering rapid development, high immunogenicity, and flexible design for preventing infectious diseases and treating various medical conditions. However, their widespread application is significantly hampered by inherent stability challenges, including molecular degradation, stringent cold-chain requirements, and limited shelf life. This review systematically examines the multidimensional factors influencing mRNA vaccine stability, encompassing molecular-level vulnerabilities of mRNA (such as hydrolysis-prone sites and nuclease sensitivity), structural and compositional stability of lipid nanoparticles (LNPs) delivery systems, and external environmental stressors (temperature, pH, nucleases). Crucially, we highlight innovative strategies to overcome these limitations, including molecular engineering of mRNA (5' cap analogs, optimized UTRs, elongated poly(A) tails, and nucleotide modifications), advanced LNP design (tunable ionizable lipids, PEGylation, and biocompatible formulations), and the application of lyophilization (freeze-drying) technology for ambient temperature storage. By integrating insights from recent advances in RNA biology, nanotechnology, and pharmaceutical engineering, this review provides a comprehensive framework for developing next-generation mRNA vaccines with enhanced stability, eliminated cold-chain dependence, and improved global accessibility-paving the way for broader clinical translation and equitable vaccine distribution.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

The stability landscape of mRNA vaccines: challenges and mitigation strategies

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief